Saturday 17 October 2026
Export BGM’s income statement to Excel — free account
BGM Group Ltd.
BGM Healthcare Drug Manufacturers Specialty & Generic
BGM Group Ltd.’s revenue for fiscal 2025 (year ended September 2025) was $37.9 million, up 51.1% from fiscal 2024.
8.65
0.06
+0.70%
Follow BGM
| Older periods | Sep '24 | Mar '25 | Sep '25 | Mar '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
2.24 | 0.85 | 0.36 | 0.43 | |
Current Ratio |
3.39 | 1.82 | 1.24 | 1.25 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.77% | 0.00% | 0.25% | |
Debt/Equity |
0.00 | 0.01 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(2.31) | (2.30) | (1.41) | (0.69) | |
Intangible Assets out of Total Assets |
0.09 | 0.67 | 0.82 | 0.84 | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
— | 0.00 | — | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(2.31) | (4.07) | (4.44) | 1.83 | |
Working Capital |
20.99 | 19.36 | 9.95 | 9.15 | |
Capital Expenditures |
(2.85) | (1.02) | (2.07) | (0.66) | |
Net Current Asset Value |
20.86 | 19.04 | 9.63 | 8.94 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.18 | 3.55 | 3.12 | 2.45 | |
Average Payables |
5.06 | 6.41 | 5.07 | 4.51 | |
Average Inventory |
6.96 | 9.87 | 12.55 | 11.80 | |
Average Assets |
58.77 | 135.81 | 242.54 | 243.20 | |
Average Common Equity |
49.53 | 119.11 | 218.12 | 222.34 |
Columns are period end dates